Biotech Companies in YC

Iorns says YC can help new founders learn how to incorporate, focus on product-market fit, and get a company started. For more established biotech founders, the program offers fundraising expertise and exposure to other fields, including AI. She says YC biotech companies had raised over $200 million at the time of the conversation.

A three-month program is too short for major experimental advances, but it can help founders define a minimum viable product, choose a go-to-market strategy, and identify the next steps. Companies may use YC funding for critical-path experiments, proof-of-concept or efficacy studies, and regulatory advice. Iorns describes de-risking as building evidence, such as showing an intervention works in a cell or animal model.

Iorns describes the end of a PhD as a point to consider whether a discovery has commercial potential, alongside the traditional postdoc route. She says university intellectual property is central to biotech, and founders may need to license it through a tech transfer office. YC can help companies work out a licensing strategy and make a case to the university.

Iorns says some biotech companies raised several million dollars in seed funding after YC, while the program still had limited data on later rounds. She contrasts this path with the established model of funds licensing discoveries, building companies internally, and hiring professional teams. She sees an opportunity to give PhD students and postdocs the mentorship and funding to become founders.

Iorns points to AI applications in biology, including predicting preclinical efficacy or toxicity and improving early clinical study design. She describes CRISPR as useful for high-throughput gene knockout screens and notes potential applications in correcting genetic defects. For longevity research, she highlights the difficulty of finding reliable human endpoints and says results from calorie restriction studies have been mixed across animal models.